exactly, they have partnered with Avion and that speaks volumes - ph 3 and just imagine the revenue stream coming in here - very positive news and plenty of sellers gone now so great base from which to propel us into double digits imo
RE: ImmuPharma drug clears a significant hurdle13 Apr 2022 10:51
big hurdle cleared can see this much much higher as Avon partnering and trial met primary end point for FDA - looking back at charts i can see it was over £1
That's an interesting thought and would not be out of the question as clearly they have been interested in the business. With rising interest rates their margin will continue to improve as metro reshape the business and its dropped from great heights from £40 per share to the low current levels. If they can continue transforming the business i don't see why this could not be on a much higher rating imo.
Things hotting up as i'm sure buyers can see that the volume has picked up and compared to the like of OSI this is due a rerate - recent director buys fuel confidence and they are in the right space with cyber security
It's in the hot sector of cyber security with sole focus on this since sale of business, mkt cap close to cash, so nothing in it for the business potential imv
I did say double digits yesterday and look where we are today- next big one in same space is FLX - in the same sector with £4.3 mil cash, mkt cap just slightly above around £4.7m and in the same space as OSI.
Must say this is excellent news and no doubt a rerate is now on the cards. They’re in the right business at the current time and 5 contract wins is just the start. Market cap has a lot of catching up to do as the business is on a growth trajectory imo
Looking forward to tomorrow as many would not have seen the TR1 till later in evening at weekend as you say and will see buyers lining up imo ahead of results